European nations weigh impact of Brexit on drug supplies

FRANKFURT/DUBLIN (Reuters) – Germany’s drug safety regulator has concluded that Brexit will not put its patients at risk of losing access to essential drugs, while Ireland has drawn up a list of 24 medicines whose supply would be most vulnerable if Britain fails to conclude a divorce deal.

Pharmaceutical tablets and capsules are arranged in the shape of a Euro currency sign on a table in this picture illustration, August 20, 2014. REUTERS/Srdjan Zivulovic/Illustration/File Photo

Between 60 and 70 percent of the 4,000 medicines on the Irish market either come from or transit through the United Kingdom.

Irish Prime Minister Leo Varadkar said a working group of health officials meeting weekly for the last two years had drawn up the watch list, but advised against stockpiling.

“It is a really important message that I want to deliver to people in Ireland today, both to patients and pharmacists, that there is no need to stockpile medicines,” Health Minister Simon Harris said at a news conference, warning that such action could inadvertently disturb the supply chain.

The country would have a supply of several weeks’ worth of most medicines if Britain crashed out on March 29 without a deal, he added.

The medicines that may be vulnerable due to special storage and transportation needs, short shelf life or single supplier reliance included intravenous foods


 »